Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma

Umemura, Hiroshi; Kaji, Tatsuru; Tachibana, Koji; Morizane, Shin

doi:10.1177/1724600819883658

Cited by 7 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, the HPLC for measuring 5-S-CD and the LC-MS/MS for measuring 6H5MI2C have the disadvantages of being expensive and requiring specialized knowledge and skills to perform, limiting their application. We have previously reported that the serum 5-S-CD levels may be a better predictive marker of nivolumab treatment e cacy than LD in patients with advanced MM [15]. Taken together with the results of the present study, serum melanin metabolites, especially 6H5MI2C measured by LC-MS/MS, appear to have the potential to be good markers for MM.…”

Section: Discussionsupporting

confidence: 80%

Comparative study of serum 6-hydroxy-5-methoxyindole-2-carboxylic acid, 5-S-cysteinyl-dopa, and lactate dehydrogenase levels as markers for malignant melanoma

Umemura,

Takiwaki,

Kikutani

et al. 2024

Preprint

View full text Add to dashboard Cite

Background With the development of novel therapies for advanced malignant melanoma (MM), biomarkers that can accurately reflect the progression of MM are needed. Recently, we have developed a method to measure the serum levels of 6-hydroxy-5-methoxyindole-2-carboxylic acid (6H5MI2C), a melanin-related metabolite, using mass spectrometry and reported that it may be a potential marker for MM. Objective In the present study, we compared the usefulness of serum levels of 6H5MI2C, 5-S-cysteinyl-dopa (5-S-CD), and lactate dehydrogenase (LD) as tumor markers for MM (n = 63). Results Among the three markers, only 6H5MI2C was significantly elevated in the metastatic group (stages III and IV) compared to the non-metastatic group (stages 0 to II). Additionally, 6H5MI2C with a cut-off level of 1.00 ng/mL showed higher sensitivity for metastatic MM than 5-S-CD and LD. Conclusions Thus, serum 6H5MI2C level has the potential to be a good marker for MM in comparison to 5-S-CD and LD.

show abstract

Section: Discussionsupporting

confidence: 80%

Comparative study of serum 6-hydroxy-5-methoxyindole-2-carboxylic acid, 5-S-cysteinyl-dopa, and lactate dehydrogenase levels as markers for malignant melanoma

Umemura,

Takiwaki,

Kikutani

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The prognosis of advanced melanoma has been improved. The study by Umemura et al compared the utility of serum 5SCD and LDH levels as markers for predicting the effects of Nivo in treating advanced melanoma, and showed that serum 5SCD levels have the potential to be an excellent predictive marker for the efficacy of Nivo therapy in patients with advanced melanoma [104]. In detail, analyzing 12 metastatic melanoma patients under Nivo therapy, they showed that serum 5SCD levels decreased in 2 of 3 patients having a partial response and increased 4 of 8 progressive cases.…”

Section: Usefulness Of 5scd In Monitoring Treatments For Melanomamentioning

confidence: 99%

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Wakamatsu

Fukushima

Minagawa

et al. 2020

IJMS

View full text Add to dashboard Cite

Melanoma is one of the most lethal and malignant cancers and its incidence is increasing worldwide, and Japan is not an exception. Although there are numerous therapeutic options for melanoma, the prognosis is still poor once it has metastasized. The main concern after removal of a primary melanoma is whether it has metastasized, and early detection of metastatic melanoma would be effective in improving the prognosis of patients. Thus, it is very important to identify reliable methods to detect metastases as early as possible. Although many prognostic biomarkers (mainly for metastases) of melanoma have been reported, there are very few effective for an early diagnosis. Serum and urinary biomarkers for melanoma diagnosis have especially received great interest because of the relative ease of sample collection and handling. Several serum and urinary biomarkers appear to have significant potential both as prognostic indicators and as targets for future therapeutic methods, but still there are no efficient serum and urinary biomarkers for early detection, accurate diagnosis and prognosis, efficient monitoring of the disease and reliable prediction of survival and recurrence. Levels of 5-S-cysteinyldopa (5SCD) in the serum or urine as biomarkers of melanoma have been found to be significantly elevated earlier and to reflect melanoma progression better than physical examinations, laboratory tests and imaging techniques, such as scintigraphy and echography. With recent developments in the treatment of melanoma, studies reporting combinations of 5SCD levels and new applications for the treatment of melanoma are gradually increasing. This review summarizes the usefulness of 5SCD, the most widely used and well-known melanoma marker in the serum and urine, compares 5SCD and other useful markers, and finally its application to other fields.

show abstract

Mechanisms of Dopamine Oxidation and Parkinson’s Disease

Segura‐Aguilar

Paris

2022

Handbook of Neurotoxicity

View full text Add to dashboard Cite

Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma

Cited by 7 publications

References 21 publications

Comparative study of serum 6-hydroxy-5-methoxyindole-2-carboxylic acid, 5-S-cysteinyl-dopa, and lactate dehydrogenase levels as markers for malignant melanoma

Comparative study of serum 6-hydroxy-5-methoxyindole-2-carboxylic acid, 5-S-cysteinyl-dopa, and lactate dehydrogenase levels as markers for malignant melanoma

Significance of 5-S-Cysteinyldopa as a Marker for Melanoma

Mechanisms of Dopamine Oxidation and Parkinson’s Disease

Contact Info

Product

Resources

About